DHTRF (DRI Healthcare Trust) Short Percentage of Float

View and export this data going back to 2023. Start your Free Trial

What is DRI Healthcare Trust Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of DRI Healthcare Trust's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DRI Healthcare Trust's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where DRI Healthcare Trust's Short Percentage of Float falls into.

DRI Healthcare Trust Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DRI Healthcare Trust (OTCPK:DHTRF) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

DHT.UN:Canada DHT.U:Canada

Address

100 King Street West, 1 First Canadian Place, Suite 7250, Toronto, ON, CAN, M5X 1B1

Website

https://www.dricapital.com

DRI Healthcare Trust is engaged in pharmaceutical royalty monetization by providing capital to inventors, academic institutions, and biopharma companies. Trust was formed to provide Unitholders with differential exposure to the pharmaceutical and biotechnology industries through ownership and acquisitions of pharmaceutical royalties. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. The Trust has concluded that it operates as one segment, primarily focused on acquiring royalty assets. Geographically the trust generates major revenue from the United States. The trust also generates Income from markets such as Japan, and the European Union.